Primary tabs

The APOE Mimetic Therapeutic Peptide CN-105 Attenuates AD Pathology and Improves Functional Outcomes in a Murine Model of Alzheimer’s Disease

Funding year(s): 
2016
Funding to date: 
$112,662

Increasing evidence suggests that brain inflammation plays an important role in mediating progression of Alzheimer’s disease (AD). In particular, it has been established that apolipoprotein E (APOE) plays a critical role in mediating neuroinflammation and disease pathology. We have developed specific APOE-based peptides that are rationally derived from the receptor-binding region of this protein, and we have demonstrated that these compounds are well tolerated, cross the blood-brain barrier, and reduce brain inflammation in preclinical models of AD and acute brain injury. We now test the hypothesis that chronic infusion of CN-105 is well tolerated, and reduces progression of pathology in a clinically relevant animal model of AD.